Zacks Investment Research Lowers Clinigen Group (OTCMKTS:CLIGF) to Sell
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
A number of other brokerages have also recently weighed in on CLIGF. ValuEngine upgraded shares of Clinigen Group from a “sell” rating to a “hold” rating in a research note on Wednesday, April 1st. Liberum Capital upgraded shares of Clinigen Group from a “hold” rating to a “buy” rating in a research note on Wednesday, March 11th.
Read More: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.